GEN Exclusives

More »

GEN Poll

More »
Jul 29, 2011

Gene Patenting Case Against Myriad Genetics

Today, the Court of Appeals for the Federal Circuit affirmed in part and reversed in part the original decision in Association for Molecular Pathology, et al. v. United States Patent and Trademark Office, et al. Specifically, it stated that Myriad Genetics' composition claims to isolated DNA were valid. What's your thoughts on this latest decision in the long-standing debate over patenting genes.

Do you agree with the Court's most recent decision validating Myriad's composition claims to isolated DNA?


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »